Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Trader Loracle Turns Bullish, Joins Longs on the Dip, HYPE Long Position Reaches $8.6 Million

Trader Loracle Turns Bullish, Joins Longs on the Dip, HYPE Long Position Reaches $8.6 Million

BlockBeatsBlockBeats2026/06/04 10:18

BlockBeats News, June 4th, according to Hyperinsight monitoring, the former HYPE's largest short seller "trader Loracle" has recently shifted his overall position from short to long, and has accumulated long positions in HYPE, ZEC, WLD, TON, ASTER, NEAR, and XMR. Among them, the long position in HYPE remains his largest allocation, opened with 2x leverage yesterday, and continues to accumulate during today's price drop, with a scale reaching $8.6 million, and still increasing.


Loracle currently holds 892,500 HYPE spot tokens (valued at approximately $60.7 million), and after switching to long positions on the futures side, his HYPE exposure has completely shifted to a unilateral bullish exposure. Currently, except for XMR, the long positions in the other 6 coins have all incurred varying degrees of unrealized losses.


Address: 0x8def9f50456c6c4e37fa5d3d57f108ed23992dae

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage